- 期刊
- OpenAccess
Treatment Outcome of Patients with Unresectable Stage IVB Head and Neck Squamous Cell Carcinoma Receiving Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil
摘要
Background: The aim of this study was to evaluate the treatment outcomes and predictors for patients with locally advanced unresectable stage IVB head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by concurrent chemoradiation (CCRT). Methods: Data from 80 patients with locally advanced unresectable stage IVB HNSCC who received TPF followed by CCRT from August 2010 to December 2012 at Kaohsiung Chang Gung Memorial Hospital were retrospectively analyzed. Clinicopathological parameters were obtained from the medical records. Results: The overall response rate to IC with TPF was 68.8%. The 12-month progression-free survival (PFS) and 2-year overall survival (OS) rates of these patients were 46% and 49.6%, respectively. Univariate analyses showed that those patients who had a clinical N classification N0/N1, could receive salvage surgery, and who responded well to IC had a significantly superior 12-month PFS rate and 2-year OS rate. Multivariate analysis also showed that clinical N classification N0/N1, undergoing salvage surgery, and being good responsiveness to IC were independent prognosticators for superior PFS and OS. Among these 80 patients, Grade 3 and Grade 4 neutropenia were noted in 13 (16%) and 9 (11%) patients, respectively. Conclusions: The results of our study suggest that IC with TPF followed by CCRT is a feasible and active treatment modality for patients with locally advanced stage IVB HNSCC, and that salvage surgery is suggested in these patients if they are operable after CCRT.
延伸閱讀
- Patil, V. M., Joshi, A., Noronha, V., Sharma, V., Zanwar, S., Dhumal, S., Kane, S., Pai, P., D'Cruz, A., Chaturvedi, P., Bhattacharjee, A., & Prabhash, K. (2016). Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). International Journal of Surgical Oncology, 2016(), 66-73. https://doi.org/10.1155/2016/6923730
- Lai, Y. M., Chao, T. K., Tseng, F. F., & Chen, Y. W. (2022). Treatment of Multiple Primary Oral Squamous Cell Carcinomas with Surgery and Concurrent Chemoradiotherapy Followed by Future Custom-made Targeting Therapy-A Case Report. 臺灣口腔顎面外科學會雜誌, 33(2), 125-136. https://www.airitilibrary.com/Article/Detail?DocID=a0000494-202206-202207140005-202207140005-125-136
- Almubarak, M., Newton, M., & Altaha, R. (2008). Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan. Journal of Oncology, 2008(), 117-120. https://doi.org/10.1155/2008/942618
- Egloff, A. M., & Grandis, J. R. (2009). Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology, 2009(), 427-438. https://doi.org/10.1155/2009/896407
- Lee, J. C., Leu, Y. S., Lee, J. C., Chang, Y. F., Huang, M. J., Chen, Y. J., & Chen, H. W. (2008). Concurrent Chemoradiotherapy Using Cisplatin and 5-Fluorouracil Alone or with Paclitaxel Followed by Adjuvant Cisplatin and 5-Fluorouracil in Nasopharyngeal Carcinoma. 中華民國癌症醫學會雜誌, 24(6), 372-379. https://doi.org/10.6588/JCOS.2008.24.6.5